Coronary interventions

Biodegradable polymer-coated versus durable polymer-coated sirolimus-eluting stents: the final 5-year outcomes of the I-LOVE-IT 2 trial

EuroIntervention 2021;16:e1518-e1526. DOI: 10.4244/EIJ-D-19-00865

Kai Xu
Kai Xu1, MD; Bo Xu2, MBBS; Changdong Guan2, MSc; Quanmin Jing1, MD; Qiangsun Zheng3, MD; Xueqi Li4, MD; Xianxian Zhao5, MD; Haichang Wang6, MD; Xuezhong Zhao7, MD; Yi Li1, MD; Jing Li1, MD; Yuejin Yang2, MD; Yaling Han1, MD, PhD; I-LOVE-IT 2 Investigators
1. General Hospital of Northern Theater Command, Shenyang, China; 2. Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China; 3. Affiliated Tangdu Hospital of the Air Force Medical University, Xi'an, China; 4. Fourth Affiliated Hospital of Harbin Medical University, Harbin, China; 5. Affiliated Changhai Hospital of the Navy Medical University, Shanghai, China; 6. Affiliated Xijing Hospital of the Air Force Medical University, Xi'an, China; 7. Jilin University First Hospital, Changchun, China

Aims: This analysis presents the final five-year results of the I-LOVE-IT 2 trial, a non-inferiority study comparing a biodegradable polymer (BP) sirolimus-eluting stent (SES) with a durable polymer (DP) SES in patients with coronary artery disease.

Methods and results: Overall, 2,737 Chinese patients eligible for coronary stenting were treated with BP-SES or DP-SES in a 2:1 ratio. Patients who were randomised to the BP-SES group were additionally re-randomised to receive either six-month or 12-month dual antiplatelet therapy (DAPT) in a 1:1 ratio. The primary endpoint was 12-month target lesion failure (TLF: cardiac death, target vessel myocardial infarction (MI), or clinically indicated target lesion revascularisation). At five years, the overall follow-up rate was 90.8%, and the cumulative incidence of TLF as the primary endpoint was similar between BP-SES and DP-SES (hazard ratio [HR] 1.01, 95% confidence interval [CI]: 0.79 to 1.28), as was that for the patient-oriented composite endpoint (PoCE: all-cause death, all MI and any revascularisation) (HR 1.03, 95% CI: 0.86 to 1.23), or definite/probable stent thrombosis (ST) (HR 0.91, 95% CI: 0.70 to 1.77). Cumulative events were also similar between the six-month DAPT and 12-month DAPT groups after BP-SES implantation.

Conclusions: I-LOVE-IT 2 showed that the five-year safety and efficacy of BP-SES and DP-SES were similar, as were those between six months and 12 months of DAPT after BP-SES implantation. 

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

adjunctive pharmacotherapyclinical trialsdrug-eluting stent
Coronary interventionsStents and scaffolds
Read next article
Relationship between fractional flow reserve value and the amount of subtended myocardium

Latest news